Maribavir

US label §2.1 (LIVTENCITY 200 mg tablets, Takeda; no UK SPC was captured in this bundle - clinician to verify against the UK SPC). The recommended dosage in adults and paediatric patients 12 years of age and older weighing at least 35 kg is 400 mg (two 200 mg tablets) taken orally twice daily with or without food. DOSE INCREASES WITH INTERACTING DRUGS: if co-administered with carbamazepine, increase to 800 mg (four 200 mg tablets) twice daily (§2.2); if co-administered with phenytoin or phenobarbital, increase to 1,200 mg (six 200 mg tablets) twice daily (§2.2); if co-administered with rifabutin, increase to 800 mg (four 200 mg tablets) twice daily (§2.3). ADMINISTRATION (§2.4): for dispersed or crushed tablets by mouth, add 30 mL of drinking water per 400 mg (60 mL for 800 mg, 90 mL for 1,200 mg), swirl gently and give before the particles settle, then rinse the container twice with 15 mL water and give the rinse; the suspension may be prepared ahead and stored at room temperature for up to 8 hours. Only two tablets can be dispersed and given via an NG or OG tube at a time. PAEDIATRIC (§8.4): the recommended dosing regimen in patients 12 years of age and older weighing at least 35 kg is the SAME as in adults - it is not expressed per kg, so no structured paediatric dose is recorded here. Safety and effectiveness have not been established in children younger than 12 years of age. Verify any under-18 use against a children's formulary. ELDERLY (§8.5): no dosage adjustment is required in patients over 65 years. The label does not state a treatment duration in the captured text (the Phase 3 trial treated for up to 8 weeks).